Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Delta 4-desaturase, sphingolipid 2 (DEGS2) is a bifunctional enzyme that acts as both a sphingolipid delta(4)-desaturase and a sphingolipid C4-hydroxylase, playing a crucial role in the biosynthesis of phytosphingolipids and ceramide in humans. DEGS2 is active in various tissues, especially in the skin, intestines, kidney, and brain. It regulates sphingolipid composition by catalyzing the formation of ceramide, a key structural and signaling lipid component. Genetic polymorphisms in DEGS2 have been linked to cognitive dysfunction in schizophrenia and to rare developmental syndromes such as Robinow syndrome. DEGS2 is part of the desaturase/hydroxylase enzyme family and its function is essential for proper sphingolipid metabolism and membrane integrity[1][2][3][4][5].
Inhibition or modulation of enzymatic activity would affect sphingolipid metabolism and ceramide composition[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Delta 4-desaturase, sphingolipid 2 (DEGS2).